Status:
UNKNOWN
Combined Inhibition of Dipeptidyl Peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/CD13) in the Treatment of Psoriasis
Lead Sponsor:
Immune Technologies & Medicine GmbH
Conditions:
Psoriasis
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
The major objective of this study is to evaluate the therapeutic effect of a topical treatment simultaneously inhibiting Dipeptidyl Peptidase IV and Aminopeptidase N (IMTM #IP10.C8) in patients with m...
Eligibility Criteria
Inclusion
- Age 18 years of age at pre-study and
- Diagnosis of plaque type psoriasis at least 3 month prior to enrolment
- Mild to moderate plaque type psoriasis with at least 2 plaques of approximately 15cm2 for which topical treatment is indicated
- Patients must be able to give written informed consent before any trial-specific procedures are performed (see Section 12.2
Exclusion
- Other type of psoriasis (e.g. erythrodermic, guttate or pustular) at enrolment
- Drug induced psoriasis at enrolment (e.g. lithium)
- Pregnant or lactating women, patients (men or women) planning a pregnancy during the duration of the study
- Systemic therapy affecting PASI or phototherapy for a period of 4 weeks prior to enrolment
- Topical therapy affecting PASI for a period of 2 weeks prior to enrolment
- Treatment with biologic agents affecting PASI for a period of 3 months prior to enrolment
- Systemic treatment with immunosuppressive agents (e.g. methotrexate, cyclosporin) or treatment with lithium, anti-malaria medication, or intramuscular gold application for a period of 4 weeks prior to enrolment
- Having a history of or an ongoing uncontrolled serious or recurring bacterial, viral, fungal, or atypical mycobacterial infection
- Having a severe medical condition that, in the judgment of the investigator, would jeopardize in any way the subject's safety following exposure to study drug
- Having the presence or history of malignancy, including lymphoproliferative disorders. Subjects with a history of fully resolved basal or squamous cell skin cancer may be enrolled
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2009
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00824980
Start Date
January 1 2009
End Date
September 1 2009
Last Update
January 19 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Zurich
Zurich, Switzerland, 8091